METTL3 incorporates m6A to circKRT17, enhancing its stabilization which in turn promotes YAP1 nuclear localization and leads to elevated expression of resistance‐related proteins P‐gp and MRP‐1 and survival‐associated proteins c‐Myc, cyclin‐D1, and Bcl2.[105] Alternatively, METTL3 indirectly represses LATS2 (a component of Hippo pathway) through upregulation of lncRNA SNHG17 by m6A modification.[106] Activation of the Hippo signaling pathway is also associated with sorafenib resistance in hepatocellular carcinoma which is mediated by RBM15B. Here, METTL3 is linked to hepatocellular carcinoma.